M65, Antagonist of PAC 1 receptor, CAS No.rp174500, Antagonist of PAC 1 receptor

CAS: rp174500 Cat. No.: rp174500

GRADE & PURITY Moligand™

Specifications

Product Name

M65, Antagonist of PAC 1 receptor, CAS No.rp174500

同義語

des-(Gln²⁵-Gln⁴¹)-maxadilan;maxadilan δ25-41

等級

Moligand™

仕様と純度

Moligand™

アクションタイプ

ANTAGONIST

作用メカニズム

Antagonist of PAC 1 receptor

CAS

rp174500

分子タイプ

ペプチド

保管と配送

保管条件

Room temperature

関連ターゲット（人間）

ADCYAP1R1 Tchem Pituitary adenylate cyclase-activating polypeptide type I receptor (0 Activities)

Discover Target: ADCYAP1R1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

遺伝情報

• Alternate Names: des-(Gln²⁵-Gln⁴¹)-maxadilan;maxadilan δ25-41
• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

No tested application protocols are provided for this SKU.

General laboratory usage for small‑molecule screening entries (non‑item‑specific):

• Stock solution: Weigh accurately; dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if necessary, sonicate briefly. Record exact concentration gravimetrically when possible.
• Working dilutions: Prepare immediately before use by serial dilution into assay buffer/media, maintaining constant vehicle (e.g., 0.1–1.0% DMSO) across controls.
• Plate handling: Use low‑bind polypropylene plates and tips to minimize adsorption. Seal plates to limit evaporation; equilibrate to assay temperature before reading.
• Stability checks: Assess short‑term stability at room temperature and at assay temperature; monitor by UPLC‑MS.
• Documentation: Record batch/lot, preparation date, and storage conditions for data traceability.

For target‑specific protocols (WB, IHC, IF, FC, etc.), not applicable to this small‑molecule listing.

Biological Roles

Item‑specific biological function, targets, or pathways are not provided in the Product Data.

General context for small‑molecule library members (non‑clinical, research use only):

• Serve as putative ligands or chemical probes in discovery assays to modulate protein function, interrogate pathways, or provide starting points for SAR.
• Employed in biophysical binding methods (e.g., SPR, MST, DSF, ligand‑observed NMR) to detect weak‑to‑moderate affinity interactions.
• When activity is observed, orthogonal counter‑screens (detergent sensitivity, redox assay panels, PAINS/REOS filters, colloidal aggregation checks) help confirm specific mechanism of action.
• ADME‑relevant properties (permeability, metabolic stability, protein binding) must be measured empirically; none are specified for this item.

Important notes:

• No claims are made about any therapeutic or diagnostic use. This product is supplied strictly for laboratory research.
• For M65 specifically, obtain the CoA/SDS or structure disclosure (if available under your agreement) to assess potential liabilities (reactive motifs, electrophiles, chelators) before biological testing.

Buffer Applications

This item is not a buffering reagent, and no acid/base properties are provided.

• No defined buffer systems, pKa values, or preparation recipes are specified for this SKU.
• For assay use, the compound may be dissolved in DMSO and diluted into your existing biological buffer (e.g., HEPES, PBS, Tris) appropriate to the target system. Maintain consistent vehicle percentage across controls and treatments.

Refer to the CoA/Spec Sheet for any solubility or stability constraints that could influence buffer selection.

Green Alternatives

Without item‑specific solvent or process requirements, green‑chemistry discussion focuses on stock preparation and assay vehicle selection.

General greener choices (literature/practice):

• Prefer minimal DMSO concentrations in assays (≤0.5% v/v) and explore ethanol or propylene glycol blends when compatible with biology and compound solubility.
• For synthetic manipulation of related analogs, consider bio‑based solvents such as 2‑MeTHF, CPME, Cyrene, or ethyl acetate in place of DMF/NMP where feasible.
• Replace acetonitrile in analytical methods with MeOH or ethanol where resolution permits; employ shorter UPLC gradients to cut solvent use.

Illustrative comparison (general):

• DMSO vs 2‑pyrrolidone/NMP: DMSO typically offers lower chronic toxicity and better biodegradability profiles than NMP; use DMSO first when possible.
• DMF/NMP replacement: 2‑MeTHF or CPME (for nonpolar tasks) and water/MeOH mixtures (for polar tasks) can reduce hazard and improve sustainability; assess solubility and reaction scope.

Operational practices:

• Scale stocks judiciously to reduce waste; use multi‑well compatible aliquots to avoid repeated freeze–thaw.
• Implement solvent recycling for preparative work and adopt micro‑scale assay development to minimize solvent/compound consumption.

Note: Final selection must be validated experimentally for M65; no item‑specific constraints are available.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation use is specified for this item.

General, non‑clinical discovery context:

• Library members like M65 are typically used in early discovery as screening compounds and potential starting points for structure–activity relationship (SAR) development.
• Any preformulation or developability assessment (solubility, chemical stability, lipophilicity, permeability) should be treated as exploratory research only and is not provided here.
• No therapeutic, diagnostic, or clinical claims are made for this product. It is for research use only.

If formulation‑like studies are performed for in vitro work:

• Prepare DMSO stocks and dilute into assay media with vehicle controls.
• For non‑aqueous test systems, consider ethanol/PEG400 or lipidic carriers as appropriate to the biology; validate compatibility empirically.

For regulated applications or cGMP use, request full specifications and compliance documentation; this listing does not provide them.

Physical Properties

Item‑specific physicochemical data were not provided in the Product Data.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa, refractive index, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/practice; not item‑specific):

• Library members are commonly supplied as solids or DMSO concentrates. Typical screening stocks: 10–50 mM in anhydrous DMSO; dilute into assay buffer immediately before use to 0.1–100 µM (assay‑dependent).
• If hydrophobic, cosolvents (≤1–2% DMSO, ≤10% acetonitrile or ethanol in aqueous media) may be used to aid dissolution; ensure vehicle controls.
• If ionizable, pH can markedly affect solubility/permeability; determine pKa experimentally or from computation before method development.
• For analytical QC, a standard set includes HPLC/UPLC purity, LC‑MS for identity, and, if solid, DSC/TGA for thermal profile (program‑level best practices).

Quality and Grades

• Supplied grade: Moligand™ (program designation)
• Purity: Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers/inhibitors: Not specified for this item; refer to CoA/Spec Sheet.

What Moligand™ typically signifies (general program description; not item‑specific specs):

• Curated small‑molecule/ligand entries intended for screening, hit validation, and SAR exploration.
• Emphasis on reliable identity confirmation (e.g., LC‑MS/HRMS) and chromatographic purity suitable for biochemical/biophysical assays.
• Practical packaging for screening workflows (e.g., dry solid or DMSO solution/vials or plates), though the exact format for this SKU is not specified here.

Quality considerations for users:

• Request the current Certificate of Analysis (CoA) for batch‑specific analytical data (purity method and % area, identity confirmation, residual solvents, water content if applicable).
• For plate‑based screening, verify plate map, concentration, and solvent composition; re‑quantify by UV or qNMR when critical.
• If photo‑ or air‑sensitive motifs are suspected, use amber vials, minimize headspace, and consider inert gas backfilling; confirm need via CoA/SDS.

Reaction and Applications

This product is positioned as a small‑molecule library/ligand entry for discovery workflows rather than a defined synthetic reagent. No manufacturer application notes were provided for this specific SKU.

Typical research applications for Moligand‑type entries (general, non‑item‑specific):

• Primary screening in biochemical/biophysical assays (enzyme inhibition, binding assays, thermal shift, SPR, NMR, DSF) to identify hits.
• Cellular assay triage at sub‑cytotoxic concentrations with careful vehicle controls and orthogonal readouts.
• Target deconvolution using chemoproteomics or affinity selection MS when suitable handles are available or can be appended.
• SAR exploration through analog procurement or synthesis once preliminary activity is observed.

Practical tips (general):

• Verify identity/purity prior to screening (UPLC‑MS). Re‑weigh solids by analytical balance; use gravimetric dosing for microgram masses.
• Prepare fresh working dilutions immediately prior to assays. Minimize freeze–thaw cycles for DMSO stocks (aliquot).
• Monitor compound aggregation (use detergent controls, dynamic light scattering, or counter‑screens) and redox cycling in ROS‑sensitive assays.

Because no structure or reactivity is provided, guidance on named reactions or functional‑group‑specific transformations cannot be given for this item.

Reaction Conditions

No reaction conditions are specified for this item, and without structural information, condition recommendations would be speculative.

General guidance if synthetic modification of a disclosed M65 structure is planned (literature/practice):

• Cross‑coupling: Typical Pd catalysts (e.g., Pd2(dba)3/XPhos or Pd(PPh3)4), bases (K3PO4, Cs2CO3), solvents (2‑MeTHF, toluene, dioxane/water), 50–110°C, 1–16 h.
• Amide coupling: EDCI/HOBt or HATU/DIPEA in DMF, DCM, or MeCN, 0–25°C then to room temperature, 1–12 h.
• Reductive amination: NaBH3CN or BH3·THF with aldehyde/amine in MeOH/THF/EtOH, pH 5–6 (AcOH), 0–25°C.
• SNAr on activated heteroarenes: bases (K2CO3, Cs2CO3) in DMF/DMSO at 60–120°C.

These are literature‑level norms and not specific to M65. Always adapt to the actual functional groups once the structure and stability profile are known.

Safety and Handling

Hazard information is not provided in the Product Data for this specific item.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / pictograms / H‑statements: Not specified for this item; refer to SDS.

General laboratory precautions (defer to SDS for authoritative guidance):

• Handle in a chemical fume hood with appropriate PPE: lab coat, safety glasses, nitrile gloves. Avoid inhalation of dust/aerosols and skin/eye contact.
• Storage incompatibilities commonly relevant to organic small molecules: strong oxidizers, strong acids/bases, and ignition sources. Keep container tightly closed.
• If supplied in DMSO, avoid contact—DMSO can facilitate dermal transport of solutes.
• First‑aid overview: In case of eye/skin contact, rinse with water for ≥15 min; remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth. Seek medical attention as needed. Always consult the SDS.
• Spill response: Absorb with inert material; avoid generating dust; collect for disposal according to institutional and local regulations.
• Waste: Dispose as organic chemical waste under applicable regulations.

Note: The definitive safety profile (including acute toxicity, sensitization, and environmental hazards) requires the current SDS for this SKU.

Solvent Selection

Item‑specific solvent preferences are not provided in the Product Data.

General selection strategy for small‑molecule screening compounds (literature/practice):

• Stock preparation hierarchy: DMSO (anhydrous) as primary; if insoluble, consider DMF, NMP, or co‑solvent blends (DMSO:water 1:1 to 1:9) and short sonication. Filter through 0.2 µm PTFE if particulate persists.
• Aqueous work: Keep final DMSO ≤0.5–1.0% v/v in biochemical assays unless higher tolerance is validated. Use surfactant‑free buffers to avoid aggregation artifacts unless aggregation is intentionally mitigated.
• Orthogonal media for analytics: MeOH, ACN, IPA for HPLC/UPLC; add 0.05–0.1% formic acid or ammonium acetate for MS compatibility as needed.

Small comparison (general):

• DMSO: highest solvating power; excellent freeze–thaw stability; may affect membrane integrity and enzyme activity at >1–2%.
• DMF/NMP: strong solvents; higher toxicity concerns; use when DMSO fails and ensure strict PPE.
• MeOH/EtOH/ACN: useful as co‑solvents for rapid aqueous dilution; volatility aids drying but may limit shelf stability.

Note: Confirm solubility and stability empirically for M65; consult CoA/SDS for any solvent restrictions or incompatibilities.

Storage and Reconstitution

• Storage conditions (Product Data): Room temperature.
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance/physical form: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (not item‑specific; verify with CoA/SDS):

• If supplied as a solid: Store tightly closed in a dry place at ambient temperature, protected from light. For hygroscopic or photosensitive materials, use desiccant and amber vials.
• If supplied in DMSO: Store at room temperature or 2–8°C as compatible with concentration and freeze point; avoid moisture ingress. Aliquot to minimize freeze–thaw cycles.
• Reconstitution (if solid): Prepare a primary stock in anhydrous DMSO (e.g., 10–50 mM). Vortex/sonicate briefly. Filter if needed through 0.2 µm PTFE. Record exact concentration.
• Working solutions: Prepare immediately before use; avoid extended storage in aqueous media unless stability is established.
• Stability: Not specified for this item; refer to CoA/Spec Sheet. Establish in‑house stability by UPLC‑MS after typical handling (bench‑top, 4°C, multiple freeze–thaw).

Research use only: Not for human or veterinary use.

Structure and Identity

Brief overview: This listing is a small‑molecule library member designated M65 (Moligand series). Item‑specific structural identifiers are not provided in the Product Data.

• SKU: rp174500; Product name: M65; Program/grade: Moligand™
• CAS: rp174500 (internal catalog identifier)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features (functional groups, ring systems, stereochemistry): Not specified for this item; refer to CoA/Spec Sheet.

Interpretive notes (general):

• “Moligand™” indicates a small‑molecule ligand/fragment‑like entry suitable for discovery screening, assay development, and SAR workflows (general program description; not item‑specific specs).
• Without a structure, 2D/3D features (heteroatoms, HBA/HBD counts, rotatable bonds) cannot be summarized for this entry. Request the current CoA/SDS for definitive identity data.

Synthetic Utility

Structure‑specific reactivity and transformations cannot be described for M65 because no functional group information is provided in the Product Data.

General considerations for library compounds (methodology context):

• If the structure is disclosed and contains common handles (aryl halides, boronates, aldehydes, amines, acids), standard platforms (Suzuki–Miyaura, Buchwald–Hartwig, amide coupling, reductive amination) enable rapid analog generation for SAR.
• Late‑stage diversification via C–H functionalization (e.g., Minisci, photoredox arylation) or SuFEx/click chemistry can expand vectors when classical handles are absent, provided the core tolerates conditions.
• Protecting‑group strategies should be minimized for speed; parallel microscale syntheses can accelerate hit expansion.

Analytical and QC:

• Use UPLC‑MS for rapid reaction screening; confirm structures by NMR (1H/13C and 2D as needed) and HRMS.
• Monitor solid‑form changes (polymorph/solvate) if the compound is isolated as a solid; this can influence assay results.

Note: Request the structure/CoA for M65 to design specific synthetic routes or diversification plans.

Target Specificity

• Target/epitope/clone/isotype/species reactivity: Not applicable; this is not an antibody or biologic.
• For this SKU, no molecular target, binding data, or selectivity profile is provided. Refer to project‑specific screening results or request additional documentation if available under your agreement.

Note: Any claims of specificity should be supported by orthogonal assays (e.g., enzymology plus biophysical binding) and counter‑screens to exclude assay artifacts.